Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis

NCT07162896 is registered in ClinicalTrials.gov with Shalamar Institute of Health Sciences as lead sponsor.

NCT NCT07162896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07162896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis
Lead sponsor
Shalamar Institute of Health Sciences
Phase
Phase 3
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
June 30, 2027
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, atopic dermatitis (ad)